Product: SKIL Antibody
Catalog: DF3088
Description: Rabbit polyclonal antibody to SKIL
Application: WB IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 77 KD; 77kD(Calculated).
Uniprot: P12757
RRID: AB_2835471

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(91%)
Clonality:
Polyclonal
Specificity:
SKIL Antibody detects endogenous levels of total SKIL.
RRID:
AB_2835471
Cite Format: Affinity Biosciences Cat# DF3088, RRID:AB_2835471.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

OTTHUMP00000213557; OTTHUMP00000213591; OTTHUMP00000213592; OTTHUMP00000213595; SKI like; SKI like oncogene; Ski like protein; SKI like proto oncogene; Ski related oncogene; Ski related oncogene snoN; Ski related protein; Ski-like protein; Ski-related oncogene; Ski-related protein; SKIL; SKIL_HUMAN; SNO; SnoA; SnoI; SnoN;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P12757 SKIL_HUMAN:

Isoform SNON and isoform SNOA are widely expressed. Highest expression is found in skeletal muscle, followed by placenta and lung. Lowest expression in heart, brain and pancreas. Isoform SNOI expression is restricted to skeletal muscle.

Sequence:
MENLQTNFSLVQGSTKKLNGMGDDGSPPAKKMITDIHANGKTINKVPTVKKEHLDDYGEAPVETDGEHVKRTCTSVPETLHLNPSLKHTLAQFHLSSQSSLGGPAAFSARHSQESMSPTVFLPLPSPQVLPGPLLIPSDSSTELTQTVLEGESISCFQVGGEKRLCLPQVLNSVLREFTLQQINTVCDELYIYCSRCTSDQLHILKVLGILPFNAPSCGLITLTDAQRLCNALLRPRTFPQNGSVLPAKSSLAQLKETGSAFEVEHECLGKCQGLFAPQFYVQPDAPCIQCLECCGMFAPQTFVMHSHRSPDKRTCHWGFESAKWHCYLHVNQKYLGTPEEKKLKIILEEMKEKFSMRSGKRNQSKTDAPSGMELQSWYPVIKQEGDHVSQTHSFLHPSYYLYMCDKVVAPNVSLTSAVSQSKELTKTEASKSISRQSEKAHSSGKLQKTVSYPDVSLEEQEKMDLKTSRELCSRLDASISNNSTSKRKSESATCNLVRDINKVGIGLVAAASSPLLVKDVICEDDKGKIMEEVMRTYLKQQEKLNLILQKKQQLQMEVKMLSSSKSMKELTEEQQNLQKELESLQNEHAQRMEEFYVEQKDLEKKLEQIMKQKCTCDSNLEKDKEAEYAGQLAELRQRLDHAEADRQELQDELRQEREARQKLEMMIKELKLQILKSSKTAKE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Chicken
91
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P12757 As Substrate

Site PTM Type Enzyme
T6 Phosphorylation
S26 Phosphorylation
K50 Sumoylation
K70 Ubiquitination
K249 Ubiquitination
K256 Ubiquitination
K342 Ubiquitination
K383 Sumoylation
K423 Ubiquitination
T426 Phosphorylation
K432 Acetylation
K440 Acetylation
K440 Ubiquitination
K446 Ubiquitination
K449 Ubiquitination
S452 Phosphorylation
S457 Phosphorylation
K463 Acetylation
K487 Methylation
K489 Sumoylation
S490 Phosphorylation
S514 Phosphorylation
K527 Sumoylation
K540 Ubiquitination
K552 Ubiquitination
K580 Ubiquitination
K601 Ubiquitination
K612 Ubiquitination
K625 Ubiquitination

Research Backgrounds

Function:

May have regulatory role in cell division or differentiation in response to extracellular signals.

PTMs:

Ubiquitinated by RNF111 and RNF165, promoting proteasomal degradation, leading to enhance the BMP-Smad signaling.

Tissue Specificity:

Isoform SNON and isoform SNOA are widely expressed. Highest expression is found in skeletal muscle, followed by placenta and lung. Lowest expression in heart, brain and pancreas. Isoform SNOI expression is restricted to skeletal muscle.

Subunit Structure:

Interacts with CPNE4 (via VWFA domain) (By similarity). Interacts with SMAD2, SMAD3 and RNF111. Isoform 1 interacts with WWP1.

Family&Domains:

Belongs to the SKI family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

References

1). DNA Methylation-Mediated GPX4 Transcriptional Repression and Osteoblast Ferroptosis Promote Titanium Particle-Induced Osteolysis. Research (Washington, D.C.), 2024 (PubMed: 39161535) [IF=8.5]

Application: WB    Species: Mouse    Sample:

Fig. 3. DNMT aberration-induced GPX4 suppression is co-regulated by KLF5. (A) Schematic diagram depicting mouse Gpx4 promoter luciferase reporter, Gpx4p-luc, the KLF5 binding motif, and its position relative to the transcription starting site. (B) Western blot. Calvarial tissues treated with control and TP (20 mg per mouse, 2 weeks) were assayed for KLF5, NCoR, SnoN, and SMRT, with β-actin serving as control. Two random samples per group were shown. Quantification beside blots was presented as mean ± SEM; n = 6; *P < 0.05, Student’s t test. (C) ChIP. Sham or TP-treated calvaria treated with or without SGI-1027 (2.5 mg/kg daily) were immunoprecipitated first with antibodies to KLF5, SMRT, NCoR, or SnoN, and then the immunoprecipitated DNA fragments were amplified through PCR with primer set specific for the KLF5 motif-containing region of the Gpx4 promoter, respectively. The non-immunoprecipitated DNA served as control (Input). PCR products were resolved on agarose gels. Quantifications on the right side were presented as mean ± SEM; n = 6; *P < 0.05, 2-way ANOVA. (D) Western blot. Primary osteoblasts (OBs) treated without or with TP (100 μg/ml) and the KLF5 inhibitor ML264 (10 μM) for 48 h were assayed for GPX4, with β-actin serving as control. Quantification below was presented as mean ± SD of 3 replicated experiments. *P < 0.05, 2-way ANOVA. (E) Luciferase assay. Primary OBs were transfected with a mouse Gpx4 promoter-luciferase reporter (Gpx4p-luc) and a Renilla luciferase reporter control, and then treated without or with TP (100 μg/ml) and SGI-1027 (10 μM) in the absence or presence of ML264 (10 μM) for 48 h. Luciferase activities of the Gpx4 promoter reporter were adjusted to Renilla luciferase activities and presented as box-and-whisker plots of 4 independent experiments. *P < 0.05, 3-way ANOVA.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.